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Abstract
Astrocytes have long been perceived only as structural and supporting cells within the central nervous system (CNS).
However, the discovery that these glial cells may potentially express receptors capable of responding to endogenous
neurotransmitters has resulted in the need to reassess astrocytic physiology. The aim of the current study was to
characterise the expression of NMDA receptors (NMDARs) in primary human astrocytes, and investigate their response to
physiological and excitotoxic concentrations of the known endogenous NMDAR agonists, glutamate and quinolinic acid
(QUIN). Primary cultures of human astrocytes were used to examine expression of these receptors at the mRNA level using
RT-PCR and qPCR, and at the protein level using immunocytochemistry. The functionality role of the receptors was assessed
using intracellular calcium influx experiments and measuring extracellular lactate dehydrogenase (LDH) activity in primary
cultures of human astrocytes treated with glutamate and QUIN. We found that all seven currently known NMDAR subunits
(NR1, NR2A, NR2B, NR2C, NR2D, NR3A and NR3B) are expressed in astrocytes, but at different levels. Calcium influx studies
revealed that both glutamate and QUIN could activate astrocytic NMDARs, which stimulates Ca
2+ influx into the cell and can
result in dysfunction and death of astrocytes. Our data also show that the NMDAR ion channel blockers, MK801, and
memantine can attenuate glutamate and QUIN mediated cell excitotoxicity. This suggests that the mechanism of glutamate
and QUIN gliotoxicity is at least partially mediated by excessive stimulation of NMDARs. The present study is the first to
provide definitive evidence for the existence of functional NMDAR expression in human primary astrocytes. This discovery
has significant implications for redefining the cellular interaction between glia and neurons in both physiological processes
and pathological conditions.
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Introduction
N-methyl D-aspartate (NMDA) receptors (NMDARs) are
ligand-gated ion channels which form one group of ionotropic
glutamate receptors in the CNS. These receptors are known to be
expressed in neurons and are activated by neurotransmitters
including glutamate and NMDA [1] as well as endogenous
excitotoxins such as quinolinic acid [2]. NMDARs exist as
heterotetrameric complexes at the surface membrane. Currently,
seven known subunits have been identified: one NR1, four NR2
(A–D) and two NR3 (A–B) subunits. In neurons, NMDARs play
an important role in facilitating learning and memory [3].
However, recent studies have revealed that these membrane
proteins may also exist in other cell types [4,5,6,7].
Although research into astrocyte NMDARs is still controversial
and functional expression of these receptors in humans is yet to be
confirmed [8,9], there has been some evidence from animal models
suggesting the involvement of astrocytic glutamate receptors in glial
cell signalling [4,10,11,12,13]. This form of glial communication
involves the induction of an intracellular calcium wave, which was
first elicited through the stimulation of cultured astrocytes with
glutamate [14]. The study showed that astrocytes could in fact
respond to extracellular neurotransmitters such as those released by
neurons via a signalling pathway that could potentially be used for
physiological glial communication although more research is
required to elucidate the exact pathways of activity.
The astrocytic glutamatergic system has also been implicated in
several neuropathological conditions including amyotrophic lateral
sclerosis (ALS) [15] and Alzheimer’s disease (AD)[16]. We have
previouslyshown thatextracellularlevelsoftheNMDAR agonist and
neurotoxin quinolinic acid (QUIN) are significantly increased in both
AD and ALS [17,18]. QUIN is an endogenous metabolite of L-
tryptophan, which is produced via the kynurenine pathway [19]. In
the brain, the amino acid L-tryptophan is normally used in protein
synthesis and metabolised to compounds such as 5-hydroxytrypta-
mine and other indoleamines. However, during neuroinflammatory
conditions, increased activity of the enzyme, indoleamine-2,3-
dioxygenase (IDO-1) directs metabolism down the kynurenine
pathway and increases the formation of QUIN [20]. Following
immune activation in the brain, QUIN is produced by activated
microglia and invading macrophages, with high levels of this
neurotoxin associated with increased neuronal [21] and glial cell
death [19]. These changes are seen in a number of diseases including
AD [17] and AIDS dementia complex [22]. As QUIN is an
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14123NMDAR agonist, the activation of glutamatergic pathway is likely to
be responsible for the cytotoxic effects observed in astrocytes [23,24].
The aim of this study was to investigate the expression of NMDARs
in human primary astrocytes as well as characterise the response of
these receptors to physiological and excitotoxic concentrations of
known NMDAR agonists. Confirming whether NMDARs exist in
astrocytes and examining the function of these receptors in glial cells
will further enhance our understanding of the functional role
astrocytes play in normal, healthy environments, as well as their
potential involvement in neuropathological conditions [25,26].
Materials and Methods
Reagents and chemicals
Dulbecco’s phosphate buffered saline (PBS) 16, RPMI medium
1640 16,0.5%Trypsin-EDTA106,Glutamax-11006,Antibiotic-
Antimycotic (AA) 1006, Trizol were obtained from GIBCO
Invitrogen (Victoria, Australia). Glucose intravenous infusion BP
50% was from AstraZeneca (Sydney, Australia). Foetal calf serum
(FCS) was obtained from Bovogen Australia. Culture flasks and
plates were purchased from Becton Dickinsonlab ware(New Jersey,
USA). QUIN and glutamate were obtained from Sigma Chemical
(Sydney, Australia). PCR reaction buffer 106, MgCl2, dNTP and
Taq DNA polymerase were obtained from Roche (Mannheim,
Germany). Permanox chamber-slides were obtained from Lab-Tek
(California, USA) and Fluoromount-G was obtained from Southern
Biotech (Alabama, USA.). The BD Calcium Assay Kit was obtained
from BD Biosciences (California, USA) and the Fluostar Optima
Fluorometer was obtained from BMG LABTECH (Victoria,
Australia). The Hepes-buffered Krebs solution, Fura-2 and pluronic
F-127, glutamate, QUIN, MK-801, and memantine were pur-
chased from Sigma-Aldrich (Missouri, USA). Trans-ACBD was
obtained from Tocris Biosciences (Bristol, UK). The Microplate
reader 680XR was obtained from Bio-Rad (California, USA).
Cell culture
Human ethics approval. Human adult brain tissue and
human foetal brain tissue were obtained following informed written
consent. This has been respective l ya p p r o v e db yt h eH u m a nE t h i c s
Committees from St Vincent’s Hospital (HREC 08284) and from the
University ofNewSouth Wales (UNSWEthic approval HREC 03187).
Isolation and culture of primary astrocytes. Human
brain tissue was obtained from adult donors post-surgery and
16- to 19-week-old foetuses. Astrocytes were prepared using a
previously described protocol [27]. Briefly, cerebral portions were
washed thoroughly with PBS and dissociated by repeated
pipettings. The suspension was centrifuged at 500 g for 5
minutes and the cell pellet resuspended in RPMI 1640 medium
containing 10% heat-inactivated FCS, 1% glutamax-1, 1%
antibiotic-antimicrobial liquid, 0.5% glucose, then plated onto
75 cm
2 culture flasks and incubated at 37uC. Medium was
changed on the 3
rd,5
th and 10
th day. The cells became confluent
after 10–12 days. Microglia were detached from the cultures by
mechanically shaking the flasks for 2 hours at 220 rpm at room
temperature and aspirated. The astrocytes were trypsinized and
replated at least three times to further purify and isolate astrocytes
from contaminating microglia and neurons. Astrocytes were left to
recover for 3 days after each passage. The astrocytes were rinsed
twice with PBS and cultured as above in uncoated flasks with the
culture medium and maintained for up to 6 weeks. For the all the
following experiments, we have used cell cultures at 3–4 weeks.
The medium was changed twice a week. Culture purity was
determined by immunofluorescence analysis with antibodies
against GFAP and more than 95% of the cells stained positive
for GFAP (Figure S1). We did not detect any staining for CD68
(microglia) and for 5B5 (fibroblasts); data not shown [28].
Isolation and culture of primary neurons. Using the same
brain samples mentioned above, human primary neurons have
been isolated and grown as we have previously described [29].
End-point RT-PCR
RNA extraction was undertaken using the Invitrogen Trizol
protocol. The cDNA was subsequently quantified via spectropho-
tometry. Original primers for the seven NMDAR subunits were
designed using ‘Primer3’ primer design software, then tested and
optimized for the PCR. The individual primers were analysed via
the BLAST database to ensure specificity of binding. Refer to
Table 1 for list of primers. For each NMDAR subunit being tested,
Table 1. Summary of Primers and product size.
END-POINT PCR
Human Target cDNA Accession no. Forward Primer (59–39) Reverse Primer (59–39) Amplicon (bp)
NR1 NM000832 CAAGTATGCGGATGGGGTGA CAGTCTGGTGGACATCTGGTA 211
NR2A NM000833 CCCCAAACTCCTCAAATCAA CAGGCGACTCAGAAATGACA 206
NR2B NM000834 ATTGGTGGCAGAGTGGATTC GGCAAAAGAATCATGGCTGT 463
NR2C NM000835 GACGAGATCAGCAGGGTAGC ATGGCCAGGATTTCATGGTA 201
NR2D NM000836 AATAATTCGGTGCCCGTGGA CCCAGACACAGTATCCACGTA 153
NR3A NM133445 GCTTGGGCATCTTAGTGAGG TACCATGACAGCAGCCAAGT 353
NR3B NM138690 TCCTACTCCTCAGCCCTCAA ATGTCGGGGAAGCTCTTCTT 296
REAL-TIME PCR
NR2A NM000833.3 GGGCTGGGACATGCAGAAT CGTCTTTGGAACAGTAGAGCAA 116
NR2B NM000834.3 TTCCGTAATGCTCAACATCATGG TGCTGCGGATCTTGTTTACAAA 104
NR2C NM000835.3 GCTGGAAGAGCGGCCCTTTGT CGCTGCTGAAGGTGTGGTTGCTCT 110
NR2D NM000836.2 CTGCAGCCAGTGGACGACACG GGGTTCGGTTGAGCTGGCTCCG 142
NR3A NM133445.2 GCCACTCCACTGGACAATGTGGC TTCGCCCCTTGGGAGTCAAACCA 113
GAPDH NM002046 TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 87
doi:10.1371/journal.pone.0014123.t001
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mixture of 49 ml containing: 10 ml of PCR reaction buffer 106,
5 ml of 2.5 mM MgCl2,2ml of 10 mM dNTP, 1 mlo f2 5m M
forward primer, 1 ml of 25 mM backward primer, 0.5 mlo f5U / ml
Taq DNA polymerase and 29.5 ml of DEPC water. PCR was
subsequently run on samples for 40 cycles under the following
conditions: denaturation (94uC for 60 s), annealing (60uC for 60 s)
and extension (72uC for 90 s). Positive controls for primers of the
NMDAR subunits involved using reverse transcribed cDNA from
a mixture of neuronal and glial brain cells.
Real-Time PCR
Human foetal astrocytes prepared from 17 to 20-week-old
foetuses (n=4) were used for real-time PCR. Human foetal
neurons were used for primer optimisation and as a positive
control for target gene expression. Primer optimisation was
performed using a standard curve derived from serial dilutions
of human foetal neuron cDNA (0.5 pg–50 ng). Multiple primer
pairs for each gene were tested and the most suitable primer
candidates were chosen by assessing the specificity of the PCR
product and efficiency. Specificity was verified by a single peak in
melting curve analysis. The real-time PCR assay for unknown
samples was performed simultaneously with positive control
samples (neurons) in the same plate.
Total RNA was extracted using the PureLink RNA Mini Kit
according to the manufacturer’s protocol. RNA quantity was
evaluated spectrophotometrically. RNA integrity was confirmed
by the Agilent 2100 electrophoresis bioanalyzer. 1 ug of total RNA
in a final volume of 20 ul was used for the synthesis of cDNA using
the Superscript Vilo cDNA Synthesis Kit in accordance with the
manufacturer’s recommendations. cDNA was diluted to a
concentration of 2.5 ng/ml with water for real-time PCR.
The NR2A, NR2B, NR2C, NR2D, NR3A, and GAPDH
mRNA transcripts were quantified using the oligonucleotide
primers for real-time PCR amplification designed based on
sequences published in the Harvard Primer Bank and the NCBI
primer-designing tool where the sequences were blasted. GAPDH
was used as the housekeeping gene. The forward and reverse
primer sequences used in this study are given in Table 1.
Primers were used at 300 nM final concentration. Briefly, 5 mlo f
the diluted synthesized cDNA together with the appropriate primers
wasaddedto10 ulBrilliantIIIUltraFastSYBRgreenQPCRMaster
mix (Agilent Technologies) to a total volume of 20 ml. A PCR
reaction master mix was prepared for each primer before dispensing
into 966PCR plate cells. No-template control (NTC) reactions were
also prepared for each gene. Real-time PCR was carried out using a
Stratagene Mx3000P (Agilent Technologies). The cycling parameters
for all genes were the following: initial denaturation at 95uCf o r
3 min, then 40 cycles of 95uCf o r2 0s ,a n d6 0 uCf o r2 0s .A l l6
transcripts were measured in each unknown sample in duplicates.
Expression values were normalised to GAPDH and are reported in
units of 2
2DCt,w h e r eDCt is the difference in Ct values between the
target and GAPDH transcripts in the same sample.
Data are presented as fold differences of mean normalised
expression values 6 standard error of mean (SEM). Differences in
the relative expression of each gene in HFA were verified by
applying the one-way ANOVA Tukey’s multiple comparison test using
GraphPad Prism 5 (GraphPad software, San Diego, CA, USA)).
Statistical significance was accepted at P,0.05; n=4.
Immunocytochemistry
The method is previously described [30,31]. Briefly, purified
foetal astrocytes were grown in Permanox chamber-slides until
around 70–75% confluence. Cells were then fixed with methanol-
acetone (1:1) solution. Membranous permeabilization was subse-
quently undertaken using 0.1% Triton-X in PBS for 10 minutes at
room temperature. The cells were then washed twice with PBS
and incubated in PBS 5% NGS overnight at 4uC. Dilutions of the
primary antibodies were made in PBS 5% NGS. Refer to Tables 2
for list of primary and secondary antibodies. Primary and
secondary antibody incubations were subsequently undertaken at
37uC for 1 hr each followed by nuclear staining using DAPI
(1 mg/ml) diluted 1/500 in water. Cover slips were mounted with
Fluoromount-G and the slides were then viewed under the
Olympus microscope BX60. Visualisation of the cells under
confocal microscopy was also undertaken using the same protocol
as immunocytochemistry. Slides were subsequently read under the
Olympus FV1000 Laser Scanning microscope.
Positive controls for immunocytochemistry involved primary
antibody staining of NMDARs in human primary neurons using
the same protocol. Negative controls were also employed via
incubations with only secondary antibodies, to detect any non-
specific secondary antibody binding as well as exclude the
presence of auto-fluorescent cells (data not shown).
Calcium influx studies using fluorometry
Human foetal astrocytes were transferred into 96-well, flat-
bottom plates and allowed to proliferate until confluence was
reached. Astrocytic dye loading with calcium indicator was
subsequently undertaken using the BD Calcium Assay Kit
following the manufacturer’s technical data sheet. 4 mM Proben-
ecid was also added to the mixture followed by a 1 hr incubation
period at 37uC. The loading solution was then removed and
replaced with HBSS containing 50 mM glycine. Addition of
selective NMDAR antagonists was undertaken 5-minutes prior to
the experiment to ensure adequate diffusion time was provided to
attain equilibrium. The calcium influx experiments were subse-
quently performed using the Fluostar Optima Fluorometer. Filter
excitation and emission was set at 485 nm and 520 nm
wavelength respectively. For each well, fluorescence was measured
via orbital scanning of 10 locations at a 3 mm radius every 0.5
seconds. The average of these readings was recorded. Baseline
fluorescence was always measured during the first 10 seconds of
the experiment, which was followed by treatment with an
NMDAR agonist (prepared in HBSS solution) via automated
syringe injection at 100 mL/s. Fluorescent readings were subse-
quently taken for an additional 90 seconds. Negative controls
included the injection of only HBSS solution without any agonist.
Concerning the NMDAR agonists used in the experiment,
glutamate and QUIN were chosen as they are endogenous ligands
found commonly in the CNS. The synthetic compound, trans-
ACBD was also selected as a treatment option due to its chemical
properties of being a very potent and highly selective NMDAR-
specific agonist (Lanthorn et al; 1990).
Calcium influx imaging
Human foetal astrocytes were trypsinized and transferred into
50 mm glass-bottom micro well dishes. When confluence was
reached, the astrocytic growth media was removed and the cells
were incubated for 1 hr at 37uC in Hepes-buffered Krebs solution
containing 2 mM Fura-2 and 4 mM pluronic F-127. After dye
loading, cells were washed thoroughly with Hepes-buffered Krebs
solution. HBSS containing 50 mM glycine was used as the
incubation medium during the experiment. Fluorescent changes
caused by calcium influx were detected via a video-based imaging
system in conjunction with an Olympus IX81 inverted microscope
and a 206 Nikon Fluor objective lens. The emission at 520 nm
was measured following excitation at 340 nm and 380 nm.
NMDA Receptors and Astrocytes
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the two different wavelengths to index true changes in calcium
entry. Baseline fluorescence was taken every 15 seconds for 2
minutes prior to addition of the NMDAR agonist using a manual
micropipette. Fluorescent measurements were subsequently taken
every 5 seconds for an additional 2 minutes following treatment.
The negative control included detecting any changes in fluores-
cence when only HBSS solution was added.
Lactase dehydrogenase (LDH) cytotoxicity assay
Human foetal astrocyteswere trypsinized and equal volumes of cell
suspension were plated into 24-well tissue culture plates. Cells were
monitored regularly and allowed to reach full confluence. Selective
NMDAR antagonists, MK-801, and memantine were then added in
triplicates to each well at varying concentrations, followed 5 minutes
later by the administration of the NMDAR agonists, QUIN and
glutamate at excitotoxic levels of 500 nM and 500 mMr e s p e c t i v e l y .
The cells were then incubated at 37uC for 24 hours after which the
media was collected and analysed for levels of LDH release.
For the LDH analysis, samples were initially diluted 1/100 and
LDH activity was assayed using a standard spectrophotometric
technique described by Koh and Choi [32].
LDH levels were also adjusted to take into account variations in
cell number using the Bradford protein assay described by
Bradford [33]. Briefly, each well was filled with 200 ml of PBS
and sonication of the cells was undertaken at 20 kHz for 15
seconds in each well. These sonicated samples were collected and a
set of standard protein was prepared using varying amounts of
BSA. Next, 60 ml of Bradford reagent (0.01% Coomassie brilliant
blue G-250, 5% ethanol, 8.5% phosphoric acid) was added to
240 ml of each sample and standard. After incubating for 30
minutes at room temperature, the samples and standards were
measured for their absorbance at 595 nm using the Microplate
reader 680XR (Bio-Rad; California, USA).
Statistical analysis
Results obtained are presented as the means 6 the standard
error of measurement (SEM). Significant differences between
results were verified using the two-tailed t-test with equal variance.
Differences between treatment groups were considered significant
if p was less than 0.05 (p,0.05).
Results
Detection of mRNA expression for different NMDAR sub-
units using RT-PCR
End-point PCR results showed that both human foetal and
adult astrocytes express the mRNA of all known NMDAR
subunits including NR1, 2a, 2b, 2c, 2d, 3a, 3b (Figure 1A). Mixed
brain cell cultures (including neurons, astrocytes, microglia,
oligodendrocytes) were used as positive controls (first column).
Semi-quantitative studies using ANOVA analysis did not reveal a
significant overall difference between adult and foetal expression of
the seven sub-types of NMDARs (p=0.13) (figure 1B).
Real-time PCR has been performed human foetal astrocytes
validating the above End-point PCR results and providing more
quantitative data. Target genes and the housekeeping gene show
high specificity as verified by a single peak in melting curve
analysis (Figures 1C). Target genes and the housekeeping gene
show high specificity as verified by a single peak in melting curve
Table 2. Summary of primary and secondary antibodies and dilutions used.
PRIMARY ANTIBODIES
Category Antibody Brand Isotype Dilution
NMDAR Subunits NR1 Abcam Polyclonal 1/100
NR1* Chemicon Monoclonal (IgG) 1/400
NR2A/B* Chemicon Monoclonal (IgG) 1/400
NR2A Chemicon Monoclonal (IgG) 1/50
NR2B Chemicon Polyclonal 1/100
NR2C Novus Polyclonal 1/100
NR2D Chemicon Monoclonal (IgG) 1/50
NR3A Upstate Polyclonal 1/100
NR3B Upstate Polyclonal 1/100
Astrocytic Markers Vimentin BD Biosciences Monoclonal (IgG) 1/200
GFAP* Novocastra Monoclonal (IgG) 1/200
GFAP* Sigma Polyclonal 1/200
Neuronal Markers MAP1 Abcam Polyclonal 1/200
SECONDARY ANTIBODIES
Antibody Type Brand Fluorescence Antibody Target Dilution
Anti-mouse Invitrogen Green* Vimentin, GFAP* 1/200
Anti-rabbit Invitrogen Green GFAP, MAP1 1/200
Anti-mouse Invitrogen Red NR2A, NR2D 1/200
Anti-rabbit Invitrogen Red* NR1, NR2B, NR2C, NR3A, NR3B,
GFAP*
1/200
*Used for the double staining NMDAR-GFAP (figure 2C).
doi:10.1371/journal.pone.0014123.t002
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PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e14123Figure 1. Detection of mRNA expression using PCR. End-point PCR - (1A) Agarose gel showing PCR bands for the various NMDAR subunits on
human foetal astrocytes (HFA) and human adult astrocytes (HAA). Mixed foetal glial and neuronal cultures were used as positive control. (1B) PCR
Semi-quantitative analysis of end-point PCR bands showing the relative mRNA expression levels of NMDAR subunits when compared to beta-actin in
human foetal astrocytes (HFA) and human adult astrocytes (HAA). Real-time PCR on HFA - (1C) Melting curves of NR2A, NR2B, NR2C, NR2D, and
NR3A transcripts. The temperature at which the rate of change of fluorescence is the greatest is defined as the melting temperature for the product.
Melting curve analysis of PCR product amplified from cDNA confirms specificity of the reaction as a single peak. (1D) Relative mRNA expression of 5
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NR2D, and NR3A was detected in HFA (Figure 1D). No more
than 10% difference in primer efficiency between the reference
gene and the target genes was obtained. NR3A mRNA expression
was significantly lower compared to NR2D mRNA expression
(p,0.05). GAPDH expression did not differ between all samples
(data not shown).
Detection of membranous expression of NMDAR
subunits in astrocytes and neurons using
immunocytochemistry and confocal microscopy
Immunocytochemistry confirmed our RT-PCR data showing
that all NMDAR subunits are also expressed in human foetal
astrocytes at the protein level (Figures 2B and 2C). Staining of
human foetal neurons were used as positive control and revealed
the presence of NMDAR expression as expected (Figure 2A).
Negative controls were performed using incubations with just the
secondary antibodies (Figures 2A, 2B and 2C). The presence of
only blue nuclei fluorescence excludes any non-specific secondary
antibody binding and also rules out the presence of auto-
fluorescent cells. Incubations with an IgG irrelevant antibody as
well as incubations with normal rabbit serum were also
undertaken and revealed no non-specific staining. Three images
were taken for each NMDAR subunit and the best image has been
displayed. In addition, single staining for MAP-2 (Figure 1A) and
GFAP (Figures 2A and 2C) was also undertaken to show the cells
were of neuronal and astrocytic origin respectively (see also Figure
S1). We then performed a double staining for GFAP and NR1 and
NR2A/B. We observed a characteristic fibrous staining of a
structural protein for GFAP and fine-pigmented immunolabelling
for the NMDAR subunits (Figure 2C). This double staining
confirms the cells expressing NMDARs are human primary
astrocytes.
Confocal microscopy revealed that the majority of NR1 and
NR2A subunits are located on the surface membrane of human
foetal astrocytes (Figure 2C). In addition, a rim of cytoplasm
mostly devoid of fluorescence can be seen separating the plasma
membrane from the central lying blue-stained nucleus. From the
confocal microscopy results, the detection of NMDARs on the
surface membrane suggests a much higher likelihood that these ion
channels are functional in astrocytes.
Calcium influx experiments
Stimulation of astrocytes using glutamate (Figure 3A) and
QUIN (Figure 3B) results in calcium influx into the cells, with the
intensity of the response increasing as the concentration of the
NMDAR-agonist increases. The intracellular movement of
calcium was significantly inhibited by pre-incubating the astrocytes
with NMDAR-specific antagonists, memantine 20 mM or MK-
801 20 mM for 5 min prior to stimulation. The inhibitory activity
of these NMDAR-specific antagonists on glutamate and QUIN
are shown in Figures 3C and 3D respectively. The glutamate
concentration of 500 mM used in the experiment is well within the
normal levels reached at the synaptic junction following neuronal
depolarisation. QUIN 1 mM is a pathophysiological concentration
found in the CNS of patients with neuroinflammatory conditions
[34]. ANOVA analysis on the quantified amplitudes of astrocytic
response showed that treatment with both glutamate and QUIN in
the presence of specific NMDA antagonists resulted in a calcium
influx response that was statistically lower than the control
(p,0.05) (Figure 3).
Real-time fluorescent imaging of astrocytes showed similar
results, with calcium influx and subsequent cell fluorescence being
detected after stimulation with trans-ACBD, which is a highly
selective NMDAR agonist (Figure 4 and avi movie Video S1). One
interesting observation when the experiments were being per-
formed was that not all astrocytes responded with calcium entry
following treatment with trans-ACBD. In the images taken using
real-time microscopy, the cell on the bottom left did not fluoresce
even after stimulation with an NMDAR agonist. This finding may
reflect the heterogeneity in astrocytic NMDAR expression
observed by immunocytochemistry.
Neurotoxicity LDH assays
Significantly higher levels of LDH were detected in the culture
supernatant following astrocyte stimulation with QUIN and
glutamate (Figure 5A), reflecting increased cell death. Linear
regression analysis showed that increasing concentrations of both
NMDAR agonists resulted in higher levels of LDH release;
glutamate (p,0.05), QUIN (p,0.05). A two-tailed t-test also
revealed that the different levels of LDH release were statistically
significant when treatment with glutamate (50 mM) and QUIN
(200 nM) was compared to control. The data were also analysed to
determine the agonist concentrations that would be most suitable
for subsequent experiments involving the addition of selective
NMDAR antagonists. The criteria for an appropriate excitotoxic
agonist concentration included ensuring sufficient amount of cell
death would occur whilst trying to maintain at least some viable
astrocytes after treatment. Using the above graphs as well as
observations of cell morphology after the excitotoxic incubation
period, the QUIN concentration of 500 nM and glutamate
concentration of 500 mM were chosen.
Pre-incubation of the astrocytes with MK-801 and memantine
prior to incubation with NMDAR agonists was able to reduce
LDH release, suggesting that the excitotoxic effects of both QUIN
and glutamate act at least partially via the NMDAR pathway
(Figure 5B). Linear regression analysis showed that both
antagonists were individually effective at reducing astrocyte
LDH release when added in the presence of excitotoxic
concentrations of glutamate (MK-801 p,0.05; memantine
p,0.01) and QUIN (MK-801 p,0.01; memantine p,0.01).
Linear regression analysis with dummy variables did not show any
statistical difference in the inhibitory activities of MK-801 or
memantine under either conditions of excitotoxic glutamate or
QUIN.
Discussion
Astrocyte ionotropic glutamate receptors (iGluRs) and in
particular NMDARs may play an important role in facilitating
glial signalling in the CNS. We have shown that adult and foetal
human primary astrocytes express all known NMDAR subunits
including NR1. NR2A, 2B, 2C, 2D and NR3A, 3B. These results
are in accordance with previous immunohistochemical studies
showing that NR1 and NR2A/B are expressed by the rodent [4]
and human astrocytic processes [8].
We also found that astrocyte calcium concentrations can be
significantly increased when stimulated with glutamate (p,0.05)
and that the mechanism of calcium elevation is at least partially
NMDAR subunits in HFA: Histogram indicating the mRNA expression of NR2A, NR2B, NR2C, NR2D and NR3A NMDAR subunits normalised to GAPDH
mRNA expression; *p,0.05 compared to NR2D and NR3A; n=4.
doi:10.1371/journal.pone.0014123.g001
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are supported by the real-time fluorescent microscopy data,
revealing the presence of calcium entry following astrocyte
stimulation with a selective NMDAR agonist (Figure 3 and 4).
Results from the fluorometry studies (Figure 3) also substantiate
this by showing the inhibition of calcium influx following the
addition of selective NMDAR antagonists (p,0.05). Furthermore,
the similar NMDAR expression profiles between adult and foetal
specimens suggest that studies on foetal astrocytes may be applied
to adult models. We previously compared simian adult astrocytes
and human foetal astrocytes for the ability to produce chemokines
and chemokines receptors and we did not found any differences
between adult and foetal cells [35]. However further research is
required to assess any potential differences between adult and
foetal NMDARs functions of individual NMDAR subunits.
The finding that NMDAR agonists such as glutamate can cause
a rise in intracellular calcium levels within astrocytes may help to
explain the mechanism of glial signalling within the CNS. Whilst
in neurons, sodium channels are the main receptors for initiating
depolarisation, it is now known that a different form of signalling
occurs in glial cells, which involves the generation of calcium
waves. Astrocytic a-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid receptors (AMPARs) and metabotropic glutamate
receptors (mGluRs) have been suggested to fulfil this role of
facilitating rises in intracellular calcium, however the results of this
study reveal that NMDAR activation may also be an important
mechanism for initiating calcium influx given that these ion
channels traditionally have much higher calcium permeability
when compared to AMPARs [10].
The glial signalling pathways triggered by this rise in
intracellular calcium are uncertain. Glutamate release has been
shown to occur following an increase of cytosolic calcium in
astrocytes [36]. Previously supported mechanisms of astrocytic
neurotransmitter efflux were centred upon cytosolic calcium
release from internal stores through the IP3 pathway following
the activation of G-protein coupled mGluRs [36]. This study
however, suggests an alternative pathway involving NMDAR
activation to achieve astrocyte intracellular calcium elevation,
Figure 2. Immunocytochemical detection of NMDARs. (Scale
bars=10 mm). (2A) Positive controls for immunocytochemistry showing
the expression of NMDARs in human foetal neurons. Immunocyto-
chemistry results showing the presence of NR1, NR2A, NR2B, NR2C,
NR2D, NR3A, NR3B in human foetal neurons at the protein level. In
addition, fibrillar staining for MAP2was also undertaken to confirm that
the cells were neurons. The blue DAPI staining is nuclei and the red
fluorescence indicates primary antibody binding to the various NMDAR
subunits. These results demonstrate that the primary antibodies for the
NMDAR subunits are functional. Negative control involved incubating
neurons with only secondary antibodies. (2B) Immunocytochemistry
results showing the presence of NR1, NR2A, NR2B, NR2C, NR2D, NR3A,
NR3B in human foetal astrocytes at the protein level. The blue DAPI
staining marks the location of the nuclei whilst the red fluorescence
shows the binding of the primary antibodies to individual NMDAR
subunits. The images reveal that all NMDAR subunits are expressed in
human astrocytes. Staining for GFAP was also undertaken to
demonstrate the cells were of astrocytic origin. Negative control
involved incubating astrocytes with only secondary antibodies (top
left). (2C) Double staining for GFAP and NR1 and NR2A/B was
performed and results show a characteristic fibrous staining of a
structural protein for GFAP and fine-pigmented immunolabelling for
the NMDAR subunits. (2D) Confocal microscopy results showing the
expression of NR1 and NR2A on the surface membrane of human foetal
astrocytes. The blue DAPI stain indicates the location of the nuclei
whilst the red fluorescence shows binding of primary antibodies to the
NMDAR subunits.
doi:10.1371/journal.pone.0014123.g002
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less, it is likely that both mGluRs and iGluRs are involved in glial
signalling and further research would be required to determine
any unique roles of each subtype.
Whilst physiological concentrations of glutamatergic neuro-
transmitters may be involved in glial communication in the CNS,
pathological conditions can also result from prolonged exposure to
excitotoxic levels of glutamate and other NMDAR agonists such as
QUIN. Concerning AD, b-amyloid (Ab) plaques are characteristic
of this condition and their presence during diseased states has been
well documented [37]. These neurotoxic lesions are often found
surrounded by extensive areas of cellular necrosis. The mechanism
by which glial excitotoxicity is caused by Ab aggregation in the
brain is still unclear [17]. One study by Guillemin [38] showed
that Ab plaques induced the expression of IDO-1 in surrounding
macrophages and microglia, resulting in the increased production
of QUIN from these cells [38]. This finding was supported by
subsequent studies revealing that the concentration of QUIN was
raised in brain sections from AD patients [17]. QUIN is also able
to increase tau phosphorylation leading to the formation of
neurofibrillary tangles. Memantine is able to reverse this effects
and [39].
From the results of the LDH cytotoxicity experiments, the ability
of selective NMDAR antagonists to reduce the level of astrocyte cell
death in the presence of high concentrations of QUIN suggests that
the excitotoxic effects of QUIN are at least partially mediated
through their actions on glial NMDARs (Figure 3). Although it is
known that QUIN is an agonist of neuronal NMDARs, this study
also postulates that the neurotoxin acts via a similar mechanism in
astrocytes to cause glial cell death. Furthermore, it has been shown
that QUIN not only over-activates NMDARs but it can also inhibit
astrocytic glutamate uptake and glutamine synthetase expression,
compounding the excitotoxic environment in the CNS during
neuroinflammatory conditions [24,40]. Therefore, the results of this
study suggest that astrocytic NMDARs may be responsible for the
glial pathology found in AD and other neurological diseases due to
their involvement in facilitating glutamate and quinolinic acid
excitotoxicity.
Figure 4. Visualization of calcium flux using fluorescent microscopy. (A) Fluorescent image taken before trans-ACBD treatment showing
non-fluorescent astrocytes when the cells were incubating in HBSS containing 50 mM glycine. Fluorescent image taken 5 seconds (B) and 10 seconds
(C) after stimulation with 1 mM trans-ACBD showing fluorescent astrocytes following treatment with a selective NMDAR agonist.
doi:10.1371/journal.pone.0014123.g004
Figure 3. Quantification of calcium flux using fluorometry. (A: left) Astrocytic response to injection of different concentrations of glutamate.
All results have been normalised and are representative of triplicate readings taken for each treatment. (A: right) Quantified amplitude of astrocytic
response to glutamate by taking the average of fluorescent readings after the treatment injection at 10 seconds. Linear regression analysis shows that
increasing the concentration of glutamate results in higher levels of intracellular calcium fluorescence being detected (p,0.01). (B: left) Astrocytic
response to injection of different concentrations of quinolinic acid. The majority of intracellular calcium increase occurred within 30 seconds of
agonist injection. All results have been normalised and are representative of triplicate readings taken for each treatment. (B: right) Quantified
amplitude of astrocytic response to quinolinic acid by taking the average of fluorescent readings after the treatment injection at 10 seconds. Linear
regression analysis shows that increasing the concentration of quinolinic acid results in higher levels of intracellular calcium fluorescence being
detected (p,0.01). (C: left) Calcium influx response to glutamate when astrocytes were pre-incubated with different antagonists. In the legend, the
black data set shows the level of fluorescence when only glutamate was added whilst all the other data sets show fluorescent readings when
astrocytes were pre-incubated with antagonists followed by glutamate stimulation at 10 seconds. (C: right) Quantified amplitude of astrocytic
response to glutamate when pre-incubated with NMDAR antagonists. ANOVA analysis with Dunnett’s post-test shows that both treatment groups
caused a calcium influx response that was statistically lower than the control (p,0.05). (D: left) Calcium influx response to quinolinic acid when
astrocytes were pre-incubated with different antagonists. In the legend, the black data set shows the level of fluorescence when only quinolinic acid
was added whilst all the other data sets show fluorescent readings when astrocytes were pre-incubated with antagonists followed by quinolinic acid
stimulation at 10 seconds. (D: right) Quantified amplitude of astrocytic response to quinolinic acid when pre-incubated with NMDAR antagonists.
ANOVA analysis with Dunnett’s post test shows that both treatment groups caused a calcium influx response that was statistically lower than the
control (p,0.05).
doi:10.1371/journal.pone.0014123.g003
NMDA Receptors and Astrocytes
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e14123In conclusion, the present study is the first to conclusively show
the functional expression of NMDARs in human primary
astrocytes. This discovery has far-reaching implications, particu-
larly in redefining the role of astrocytes in both physiological
progresses and pathological conditions.
Supporting Information
Video S1. Real-time imaging of astrocytes showed similar
results, with calcium influx and subsequent cell fluorescence being
detected after stimulation with trans-ACBD.
Found at: doi:10.1371/journal.pone.0014123.s001 (2.80 MB
MOV)
Figure S1. Purity of primary cultures of human fetal astrocytes.
GFAP immunocytochemical staining of purified human foetal
primary astrocyte cultures (6400). GFAP IgG1 mAb (Novocastra)
was used for this staining.
Found at: doi:10.1371/journal.pone.0014123.s002 (1.35 MB
TIF)
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Figure 5. Neurotoxicity and neuroprotection assays. Different concentrations of glutamate (A: top) and quinolinic acid (A: bottom) were
used to induce excitotoxic cell death in astrocytes, which were quantified by measuring LDH release after 24 hours. Protein levels were also
calculated using the Bradford assay to standardise the cell numbers within each well. Significance *p,0.05 compared to control (n=3 for each
treatment group). (B: top) Level of LDH release after 24 hrs when astrocytes were incubated with 500 mM of glutamate and varying concentrations of
different selective NMDAR antagonists. Employing two-tailed t-test analyses showed that all treatment groups of MK-801 and memantine, even at
concentrations of 0.1 mM resulted in reduced LDH levels in the supernatant. Significance */
0 p,0.05 compared to control (n=3 for each treatment
group). (B: bottom) Level of LDH release after 24 hrs when astrocytes were incubated with 500 nM of QUIN and varying concentrations of different
selective NMDAR antagonists. Using two-tailed t-test analyses revealed that all MK-801 treatment groups resulted in reduced LDH production but
only memantine concentrations above 0.5 mM were statistically significant in decreasing LDH levels. Significance */
0 p,0.05 compared to control
(n=3 for each treatment group).
doi:10.1371/journal.pone.0014123.g005
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